NOVARTIS INDIA LTD.

Novartis India Limited, now known as Evonile Pharma Limited, has announced an earnings call scheduled for November 04, 2026, at 2:30 PM IST. The call will focus on discussing the company's unaudited financial results for the quarter and half-year ended September 30, 2026. Investors and analysts can join the call using provided dial-in numbers or via a registration link on the company's website. Management contacts for the call include Bhagwat Singh Deora (CFO) and Jason D’Souza (President – BD, M&A and IR).

Novartis India Ltd (now Evonile Pharma Limited) has announced the appointment of Mr. Gagan Sharma as Senior Management Personnel, effective October 26, 2026. Mr. Sharma, who holds the position of President - Specialty Business, brings over 30 years of pharmaceutical industry experience. His expertise spans commercial functions, strategic growth, business transformation, and portfolio management. Previously, he was the Therapy Area Head for Gene Therapy, Immunology, and In-Market Brands at Novartis Healthcare Private Limited and a member of its India Leadership Team.

Evonile Pharma Limited (formerly Novartis India Limited) announced that its Board of Directors has approved a Rights Issue to raise funds up to ₹9,000 million (₹900 Crore). The funds will be raised through the issuance and allotment of partly paid-up equity shares. A Rights Issue Committee has been constituted to finalize the terms, including issue size, price, and record date. The company also approved a postal ballot notice for shareholders and launched its new corporate website, www.evonilepharma.com.

Evonile Pharma Limited (formerly Novartis India Limited) announced its Board of Directors has approved a Rights Issue to raise up to ₹9,000 million (₹900 Crore). The funds will be raised through the issuance and allotment of partly paid-up equity shares. A Rights Issue Committee has been constituted to finalize the terms and conditions of the issue. The company also approved the adoption of its new corporate website, www.evonilepharma.com, and a postal ballot notice for shareholder approval.

Evonile Pharma Limited (formerly Novartis India Limited) announced its Board of Directors has approved a Rights Issue to raise funds up to ₹9,000 million (₹900 Crore). The funds will be raised through the issuance and allotment of partly paid-up equity shares. The Board also approved the constitution of a Rights Issue Committee to finalize the terms and conditions, including issue size, price, and record date. Additionally, the company approved a postal ballot notice for shareholder approval and the launch of its new corporate website, www.evonilepharma.com. The meeting was held on October 08, 2026.

Novartis India Ltd (now Evonile Pharma Limited) has informed BSE that its Board of Directors will convene a meeting on Thursday, October 08, 2026. The main purpose of the meeting is to consider and approve a proposal to raise funds through a rights issue. This rights issue would involve the issuance of equity shares, each with a face value of ₹5, to eligible equity shareholders. The fund-raising initiative is contingent upon receiving all necessary regulatory, statutory, and other applicable approvals. The company also reiterated that the trading window for designated persons is already closed from October 01, 2026, until November 05, 2026, due to the upcoming unaudited financial results for the quarter and nine months ended September 30, 2026.

Novartis India Limited has officially changed its name to Evonile Pharma Limited, effective October 01, 2026. This change follows shareholder approval via a special resolution at the 78th Annual General Meeting held on September 24, 2026, and subsequent approval from the Ministry of Corporate Affairs (MCA). The Memorandum and Articles of Association have been amended to reflect the new name. The company will continue to operate under the new name, Evonile Pharma Limited, and has updated its website with the amended constitutional documents. Stakeholders are advised to verify the company's latest status on the MCA website.

Novartis India Limited has announced that its Board of Directors will convene on Tuesday, November 03, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results for the quarter and half-year ended September 30, 2026. Concurrently, the company is implementing a closure of the trading window for its designated persons, insiders, connected persons, and their immediate relatives. This closure will be effective from October 01, 2026, and will be lifted 48 hours after the financial results are officially declared to the stock exchange. This measure is in compliance with SEBI regulations concerning insider trading.

Novartis India Ltd has announced that its Board of Directors will convene on November 3, 2026. The primary agenda item for this meeting is to consider and approve the company's Unaudited Financial Results for the quarter and half-year ended September 30, 2026. In line with SEBI regulations, the trading window for designated persons will be closed from October 1, 2026, and will reopen 48 hours after the financial results are disclosed to the stock exchange. The company will also make this information available on its website.

Novartis India Ltd has filed the voting results and the Scrutinizer's Report for its 78th Annual General Meeting (AGM) held on September 24, 2026. The report details the voting outcomes on two ordinary resolutions: the adoption of the Audited Balance Sheet and Statement of Profit and Loss for the financial year ended March 31, 2026, and the regularization of Mr. Ashok Bhatia's appointment as a Non-Executive Director. Both resolutions were passed with overwhelming support from shareholders, with minimal dissenting votes from the public non-institutional category on the second resolution.